Updating results

641 results

Sort: Relevance | Date

Electrical stimulation to improve muscle strength in non-neurological chronic conditions: interventional procedure consultation

We are listening to your views on this interventional procedures guidance. Comments close 05 March 2020.

Interventional procedures guidance In consultation

Axonics sacral neuromodulation system for bladder control in people with symptoms of overactive bladder: draft guidance

We are listening to your views on this medical technologies guidance. Comments close 13 March 2020.

In consultation

Faltering growth: quality standard consultation

We are listening to your views on this quality standard. Comments close 21 February 2020.

Quality standard In consultation

Suspected neurological conditions: quality standard consultation

We are listening to your views on this quality standard. Comments close 11 March 2020.

Quality standard In consultation

Upadacitinib for treating moderate to severe rheumatoid arthritis [ID1400]: appraisal consultation

We are listening to your views on this technology appraisal guidance. Comments close 21 February 2020.

Technology appraisal guidance In consultation

Preterm labour and birth: surveillance consultation

We are listening to your views on this NICE guideline. Comments close 26 February 2020.

NICE guideline In consultation

Behaviour change: digital and mobile health interventions: draft guidance consultation

We are listening to your views on this NICE guideline. Comments close 06 March 2020.

NICE guideline In consultation

Acute coronary syndromes: draft guidance consultation

We are listening to your views on this NICE guideline. Comments close 27 March 2020.

NICE guideline In consultation

Pembrolizumab with axitinib for untreated advanced renal cell carcinoma [ID1426]: appraisal consultation

We are listening to your views on this technology appraisal guidance. Comments close 04 March 2020.

Technology appraisal guidance In consultation

Crisaborole for treating mild to moderate atopic dermatitis in people aged 2 years and older (ID1195)

In development [GID-TA10435] Expected publication date: 03 June 2020

Technology appraisal guidance In development

Suspected neurological conditions

In development [GID-QS10082] Expected publication date: 03 July 2020

Quality standard In development

Faltering growth

In development [GID-QS10083] Expected publication date: 02 June 2020

Quality standard In development

Community pharmacies: promoting health and wellbeing

In development [GID-QS10115] Expected publication date: 02 June 2020

Quality standard In development

Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinoma

In development [GID-IPG10067] Expected publication date: TBC

Interventional procedures guidance In development

ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]

In development [GID-TA10259] Expected publication date: TBC

Technology appraisal guidance In development

Duvelisib for treating relapsed chronic lymphocytic leukaemia [ID1083]

In development [GID-TA10260] Expected publication date: TBC

Technology appraisal guidance In development

Selumetinib for treating differentiated thyroid cancer ID1079

In development [GID-TA10207] Expected publication date: TBC

Technology appraisal guidance In development

Talacotuzumab for untreated acute myeloid leukaemia [ID1262]

In development [GID-TA10249] Expected publication date: TBC

Technology appraisal guidance In development

NY-ESO-1 T-cells for treating synovial sarcoma ID1286

In development [GID-TA10205] Expected publication date: TBC

Technology appraisal guidance In development

Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]

In development [GID-TA10251] Expected publication date: TBC

Technology appraisal guidance In development

Listeria monocytogenes vaccine for previously treated malignant pleural mesothelioma ID1353

In development [GID-TA10320] Expected publication date: TBC

Technology appraisal guidance In development

Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297

In development [GID-TA10311] Expected publication date: TBC

Technology appraisal guidance In development

Fenfluramine for treating Dravet syndrome [ID1109]

In development [GID-TA10373] Expected publication date: TBC

Technology appraisal guidance In development

Lorlatinib for treating ALK-positive advanced non-small-cell lung cancer [ID1338]

In development [GID-TA10317] Expected publication date: TBC

Technology appraisal guidance In development

Fedratinib for splenomegaly and symptoms in myelofibrosis [ID1501]

In development [GID-TA10406] Expected publication date: 24 March 2021

Technology appraisal guidance In development

Non-bisphosphonates for treating osteoporosis [ID901]

In development [GID-TA10072] Expected publication date: TBC

Technology appraisal guidance In development

Heart valve disease presenting in adults: investigation and management

In development [GID-NG10122] Expected publication date: 20 May 2021

NICE guideline In development

Carfilzomib with dexamethasone and lenalidomide for treating multiple myeloma after at least 1 previous therapy [ID1493]

In development [GID-TA10510] Expected publication date: TBC

Technology appraisal guidance In development

Larotrectinib for treating advanced solid tumours with TRK fusions [ID1299]

In development [GID-TA10229] Expected publication date: 27 May 2020

Technology appraisal guidance In development

Erenumab for preventing migraine [ID1188]

In development [GID-TA10302] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab with bevacizumab for untreated unresectable or advanced hepatocellular carcinoma [ID1655]

In development [GID-TA10565] Expected publication date: 16 December 2020

Technology appraisal guidance In development

Upadacitinib for treating moderate to severe rheumatoid arthritis [ID1400]

In development [GID-TA10389] Expected publication date: TBC

Technology appraisal guidance In development

Esketamine for treatment-resistant depression (ID1414)

In development [GID-TA10371] Expected publication date: TBC

Technology appraisal guidance In development

Budesonide for treating active eosinophilic oesophagitis [ID1202]

In development [GID-TA10372] Expected publication date: 08 July 2020

Technology appraisal guidance In development

Durvalumab in combination for untreated extensive stage small-cell lung cancer [ID1618]

In development [GID-TA10493] Expected publication date: 16 December 2020

Technology appraisal guidance In development

Indoor air quality at home

In development [GID-QS10113] Expected publication date: 20 October 2020

Quality standard In development

Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]

In development [GID-TA10623] Expected publication date: TBC

Technology appraisal guidance In development

Ozanimod for treating relapsing-remitting multiple sclerosis [ID1294]

In development [GID-TA10299] Expected publication date: 22 July 2020

Technology appraisal guidance In development

QAngio XA 3D/ QFR and CAAS vFFR imaging software for assessing the functional significance of coronary obstructions during invasive coronary angiography

In development [GID-DG10034] Expected publication date: 30 September 2020

Diagnostics guidance In development

Testing strategies for Lynch syndrome in people with endometrial cancer

In development [GID-DG10033] Expected publication date: 29 July 2020

Diagnostics guidance In development

Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm ID1556

In development [GID-TA10482] Expected publication date: 24 March 2021

Technology appraisal guidance In development

Acne Vulgaris: Management

In development [GID-NG10109] Expected publication date: 13 January 2021

NICE guideline In development

Minimally invasive radical hysterectomy for early stage cervical cancer

In development [GID-IPG10131] Expected publication date: 18 March 2020

Interventional procedures guidance In development

PneuX for preventing ventilator-associated pneumonia in intensive care

In development [GID-MT528] Expected publication date: 27 March 2020

Medical technologies guidance In development

Siponimod for treating secondary progressive multiple sclerosis [ID1304]

In development [GID-TA10436] Expected publication date: 27 May 2020

Technology appraisal guidance In development

Multiple myeloma - lenalidomide (maintenance, post autologous stem cell transplantation) [ID475]

In development [GID-TAG430] Expected publication date: 28 October 2020

Technology appraisal guidance In development

Human alpha1-proteinase inhibitor for treating emphysema ID856

In development [GID-HST10017] Expected publication date: TBC

Highly specialised technologies guidance In development

Thyroid cancer: assessment and management

In development [GID-NG10150] Expected publication date: 04 April 2022

NICE guideline In development

Endo-Sponge for treating colorectal anastomotic leakage

In development [GID-MT539] Expected publication date: 01 September 2020

Medical technologies guidance In development

Elosulfase alfa for treating mucopolysaccharidosis type IVa (review of HST2) [ID1643]

In development [GID-HST10027] Expected publication date: 11 November 2020

Highly specialised technologies guidance In development